Serum trough concentration threshold and risk factors of cefoperazone-induced coagulopathy in critically ill patients: A retrospective case-control study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cefoperazone-induced coagulopathy in critically ill patients often occurs around day 6. High APACHE II scores, liver issues, and serum concentrations above 87.765 mg/L increase risk, while vitamin K1 is protective.
Area Of Science
- Pharmacology
- Critical Care Medicine
- Clinical Chemistry
Background
- Cefoperazone is an antibiotic used in critical care settings.
- Coagulopathy is a potential adverse effect of certain antibiotics, including cefoperazone.
- Identifying risk factors and thresholds for cefoperazone-induced coagulopathy is crucial for patient safety.
Purpose Of The Study
- To identify risk factors for cefoperazone-induced coagulopathy in critically ill patients.
- To determine the serum trough concentration threshold associated with this adverse event.
- To evaluate the efficacy of vitamin K1 prophylaxis.
Main Methods
- A retrospective case-control study involving 113 intensive care unit patients treated with cefoperazone.
- Patients were categorized into normal and coagulopathy groups based on prothrombin time.
- Univariate analysis, ROC curve analysis, and multivariate logistic regression were used to analyze data.
Main Results
- The incidence of cefoperazone-induced coagulopathy was 34.5% (39/113 patients), with median onset around day 6.
- The serum trough concentration threshold for coagulopathy was 87.765 mg/L.
- Risk factors included higher APACHE II scores, hepatic impairment, and serum concentrations ≥ 87.765 mg/L; prophylactic vitamin K1 was protective.
Conclusions
- Cefoperazone-induced coagulopathy typically manifests around day 6 in critically ill patients.
- Patients with APACHE II scores > 25, hepatic impairment, and cefoperazone trough concentrations ≥ 87.765 mg/L are at increased risk.
- Prophylactic administration of vitamin K1 effectively prevents this adverse reaction.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...